Skip to content
yes i take peptides.
Library/For Energy/Sermorelin
Rx · prescription required⚠ IGF-1 Elevation+2 more

Sermorelin

A truncated GHRH (1-29 amino acids). We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 13 minEvidence ●●●○○Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts Sermorelin on your decision board.

The Sermorelin Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
Rx
Class
IGF-1 Elevation
Evidence
3/ 5●●●○○
Original FDA approval
1997 therapeutic (Geref); 1990 diagnostic
Current FDA status
$19 ↓
Half-life
$19 ↓
⚠ WADA-banned · IGF-1 Elevation
Read this if
  • a tele-clinic put you on a "longevity" stack and sermorelin is the cheapest line on the invoice
  • you want the most-physiologic GH peptide before stepping up to CJC-1295 or tesamorelin
  • you're a 50-something woman whose hormone clinic just added it after menopause
Skip this if
  • **a mail-order tele-clinic shipped you pre-reconstituted vials** — sermorelin's half-life in solution is short (~30 min freshly mixed; <50% potency by 24 hr at room temp). Mail-order pre-reconstituted vials are frequently sub-potent. Reconstitute the lyo powder yourself + use within 7 days refrigerated, or you're injecting buffer with degraded peptide
  • **a clinic is selling you 'weekly sermorelin'** — the label doesn't match the molecule's pharmacology. Half-life is ~10–20 min in plasma; you cannot dose weekly and get a daily GH pulse. If it's labeled weekly, they're selling CJC-1295-with-DAC or a different molecule altogether
  • you compete in a tested sport — WADA-banned
  • you have active or recent cancer
  • you're a healthy adult expecting the effects of HGH itself — sermorelin is meaningfully weaker
The 4 ways you can buy Sermorelin
Brand
✗
Not available
No current FDA-approved sermorelin brand; the dominant clinical channel is compounded.
Compounded 503A
✓
Rx
$150–$400/mo
Pharmacy-grade; sermorelin has the longest clinical-use history of the GH-secretagogue family.
RUO (research-only)
✓
Sold 'for research only'
$30–$100/mo
The cheap-fallback; identity-failures vs CJC-1295 or Mod GRF 1-29 are documented.
Gray market
✓
Unregulated overseas import
$10–$25/mo
Same upstream synthesis as RUO. Crypto/Wise pay; one box covers many months.
Click any lane for the full Sourcing breakdown.
First 90 days · Sermorelin
Weeks 1–2
Sleep depth shifts within days for the GH-secretagogue class (CJC, ipamorelin, sermorelin, hexarelin). If sleep hasn't deepened by week 2, the rest of the protocol probably won't move either.
Weeks 4–8
Subjective recovery and energy improvements. Body composition shifts modestly — slight muscle gain, slight fat loss if diet allows.
Week 12 — decide
Bloodwork: IGF-1 is the objective check. If IGF-1 hasn't moved, the protocol isn't working at this dose. Side effect bookkeeping: water retention, joint stiffness, any glucose changes.
Quit if
  • IGF-1 climbs above ~300 ng/mL (cancer-risk territory at the upper end).
  • Significant water retention or new carpal-tunnel-style symptoms.
  • New or worsening insulin resistance (fasting glucose creep).
  • 12 weeks with no IGF-1 movement and no subjective change.
Identity

What it is.

Sermorelin is a 29-amino-acid fragment of GHRH — the hypothalamic hormone that tells the pituitary to release growth hormone. The fragment is the active region of the parent molecule. Same receptor, same job.

It was approved by the FDA in 1997 as Geref for pediatric growth-hormone deficiency. Merck pulled the brand from the US market in 2008 — not because it stopped working, but because the commercial case stopped working. It now lives almost entirely in the 503A compounding pharmacy world, prescribed off-label for adult anti-aging and "GH boosting."

Mechanically, it's the most physiologic of the GH secretagogues. It nudges your own pituitary, preserves the natural pulse pattern, and is shut down by the body's normal somatostatin feedback loop. That's the pitch versus injecting recombinant HGH directly. WADA-banned in and out of competition.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Sermorelin actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the Sermorelin report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the Sermorelin report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
Original FDA approval
1997 therapeutic (Geref); 1990 diagnostic
Current FDA status
$19 ↓
Half-life
$19 ↓
Reconstituted half-life in solution
$19 ↓
Mail-order pre-reconstituted vials
$19 ↓
'Weekly sermorelin' on a clinic invoice
$19 ↓
IGF-1 rise (adults)
$19 ↓
WADA status
$19 ↓
Anti-aging RCTs
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the Sermorelin report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Sermorelin report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the Sermorelin report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the Sermorelin report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
  2. 02Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical interventions in aging. 2006;1(4):307-8. PMID: 18046908.
  3. 03Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis. 2021;13(11-12):1871-1887. PMID: 34665524.
  4. 04Chang Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of translational medicine. 2021;9(5):406. PMID: 33842627.
  5. 05Prakash A, et al. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 1999;12(2):139-57. PMID: 18031173.
+Show all 60 citations
  1. 06Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
  2. 07Cristea CD, et al. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical biochemistry. 2023;682:115336. PMID: 37806509.
  3. 08González-López NM, et al. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomedical chromatography : BMC. 2023;37(12):e5741. PMID: 37688464.
  4. 09Otin J, et al. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis. Electrophoresis. 2023;44(9-10):807-817. PMID: 36787346.
  5. 10Gesmundo I, et al. Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells. International journal of molecular sciences. 2025;26(7). PMID: 40244089.
  6. 11Coppieters G, et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of pharmaceutical and biomedical analysis. 2022;214:114726. PMID: 35298973.
  7. 12Thomas A, et al. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of mass spectrometry : JMS. 2024;59(1):e4996. PMID: 38197510.
  8. 13Esposito P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced drug delivery reviews. 2003;55(10):1279-91. PMID: 14499707.
  9. 14Grossman A, et al. Growth hormone releasing hormone. Clinics in endocrinology and metabolism. 1986;15(3):607-27. PMID: 2429796.
  10. 15Barkan A. When the light turns blue. Endocrinology. 1997;138(11):4527-9. PMID: 9348173.
  11. 16Knoop A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry. 2016;408(12):3145-53. PMID: 26879649.
  12. 17Barabutis N. A glimpse at growth hormone-releasing hormone cosmos. Clinical and experimental pharmacology & physiology. 2020;47(9):1632-1634. PMID: 32289177.
  13. 18Louzada RA, et al. GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(25):e2209810120. PMID: 37307472.
  14. 19Thomas A, et al. Probing for peptidic drugs (2-10 kDa) in doping control blood samples. Analytical science advances. 2022;3(7-8):235-243. PMID: 38716080.
  15. 20Xu Y, et al. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. The Journal of international medical research. 2012;40(4):1217-26. PMID: 22971474.
  16. 21Uçaktürk E, et al. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2026;268:117207. PMID: 41138283.
  17. 22de Zegher F, et al. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. The Journal of clinical endocrinology and metabolism. 1990;71(2):520-2. PMID: 2143200.
  18. 23Costoya J, et al. A novel approach for the treatment of AML, through GHRH antagonism: MIA-602. Reviews in endocrine & metabolic disorders. 2025;26(3):483-491. PMID: 39417961.
  19. 24Venhuis BJ, et al. Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. Drug testing and analysis. 2016;8(3-4):398-401. PMID: 26456392.
  20. 25Thomas A, et al. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug testing and analysis. 2015;7(11-12):990-8. PMID: 26382721.
  21. 26Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639.
  22. 27Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. PMID: 41880199.
  23. 28Byrnes ME. Reversed-phase high-performance liquid chromatography. A semipreparative methodology. Methods in molecular biology (Clifton, N.J.). 1994;36:37-52. PMID: 7535163.
  24. 29Muñoz-Moreno L, et al. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH). The Prostate. 2022;82(8):933-941. PMID: 35322894.
  25. 30Sigalos JT, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health. 2017;11(6):1752-1757. PMID: 28830317.
  26. 31Belavgeni A, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(44):22269-22274. PMID: 31611400.
  27. 32Cai R, et al. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides. 2022;150:170716. PMID: 34952135.
  28. 33Liang WC, et al. Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(11):6067-6074. PMID: 32123064.
  29. 34Pont L, et al. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. Journal of chromatography. A. 2020;1631:461548. PMID: 32971474.
  30. 35Muñoz-Moreno L, et al. Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers. International journal of molecular sciences. 2024;25(20). PMID: 39456984.
  31. 36Gaumond SI, et al. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia. Oncotarget. 2024;15:248-254. PMID: 38588464.
  32. 37Condor Capcha JM, et al. Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(48):e2308342120. PMID: 37983492.
  33. 38Recinella L, et al. Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice. Peptides. 2021;142:170582. PMID: 34051291.
  34. 39Wu HM, et al. Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†. Biology of reproduction. 2022;106(1):145-154. PMID: 34792103.
  35. 40Rieger AC, et al. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(4). PMID: 33468654.
  36. 41Recinella L, et al. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific reports. 2020;10(1):732. PMID: 31959947.
  37. 42Granato G, et al. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells. Frontiers in immunology. 2023;14:1231363. PMID: 37649486.
  38. 43Zhang C, et al. Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung. 2019;197(5):541-549. PMID: 31392398.
  39. 44Muñoz-Moreno L, et al. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. The Prostate. 2018;78(12):915-926. PMID: 29748961.
  40. 45Rodrigues-Dos-Santos K, et al. Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress. Molecular and cellular endocrinology. 2021;535:111379. PMID: 34252492.
  41. 46Cervini LA, et al. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. Journal of medicinal chemistry. 1998;41(5):717-27. PMID: 9513600.
  42. 47Barabutis N, et al. GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020;52(5):336-339. PMID: 32403147.
  43. 48Xiong X, et al. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(12):6726-6732. PMID: 32156725.
  44. 49Chu WK, et al. Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(50):14396-14401. PMID: 27911838.
  45. 50Lance VA, et al. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochemical and biophysical research communications. 1984;119(1):265-72. PMID: 6231028.
  46. 51Qin YJ, et al. Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(51):18303-8. PMID: 25489106.
  47. 52Sigdel M, et al. Growth hormone - releasing hormone antagonists induce autophagy in cancer cells. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2025;82:101668. PMID: 41075421.
  48. 53Gan J, et al. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(51):14745-14750. PMID: 27930339.
  49. 54Qin YJ, et al. Induction of Apoptosis in Pterygium Cells by Antagonists of Growth Hormone-Releasing Hormone Receptors. Investigative ophthalmology & visual science. 2018;59(12):5060-5066. PMID: 30357400.
  50. 55Thounaojam MC, et al. Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(50):13248-13253. PMID: 29180438.
  51. 56Ross RJ, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet (London, England). 1987;1(8523):5-8. PMID: 2879138.
  52. 57Cen LP, et al. Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(28). PMID: 34244423.
  53. 58Recinella L, et al. Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD. Molecular psychiatry. 2021;26(12):7465-7474. PMID: 34331008.
  54. 59Neyzi O, et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:16-21; discussion 22. PMID: 8329826.
  55. 60Wang H, et al. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. International journal of cancer. 2018;142(11):2394-2404. PMID: 29435973.
The Sermorelin Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →